Interleukin-4 Receptor Targeting Peptide AP

Not For Human Use, Lab Use Only.

C44H82N20O13S2

SKU KSP-20713 Category

Sequence 3 letters:

H-Cys-Arg-Lys-Arg-Leu-Asp-Arg-Asn-Cys-OH

Sequence:

H-CRKRLDRNC-OH

Cas No. :

Molecular Formula:

C44H82N20O13S2

Molecular Weight:

1163.37

Description

Atherosclerotic plaque (AP) homing nonapeptide (CRKRLDRNC) was identified after cycles of ex vivo phage display screening on human atheroma tissue and further validated for homing to the atherosclerotic plaques in an in vivo murine model. A homology sequence search identified the AP binding sequence KRLDRN motif corresponding to the Interleukin-4 (IL-4) . Its receptor, IL-4R, is abundantly expressed by glioma cells thereby presenting the CRKRLDRNC as a promising tool for glioma targeting. Park et al. showed promising results with the AP peptide conjugated to doxorubicin containing microbubbles and nanoliposomes as a proof-of-concept for glioma targeted imaging and therapy using the U87MG in vitro models. AP peptide conjugated to doxorubicin containing liposomes showed also enhanced antitumor activity in in vivo model of human lung cancer.

Reference

  • Hong HY, Lee HY, Kwak W, Yoo J, Na MH, So IS, et al. Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis. J Cell Mol Med. 2008;12(5B):2003-14
Categories:
Product Quote Form
Please enable JavaScript in your browser to complete this form.
Name
Email